Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 in neovascular age-related macular degeneration (Phase II, single-arm, China)
CTR20254470Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efdamrofusp alfa in exudative macular degeneration, sponsored by InnoCare Pharma. Primary endpoint: Proportion of participants with BCVA loss <15 ETDRS letters from baseline in the study eye. Started Dec 2025; status: active.
02
Drugs
efdamrofusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20254470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254470.